Non-interventional Study on the Use of ILARIS® (Canakinumab) Among Familial Mediterranean Fever and Still's Disease Patients Across Europe and Israel
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Healthy Volunteers: f
View:
• Pediatric or adult patients who were prescribed canakinumab before October 2021 and received canakinumab for at least 6 months for the treatment of FMF or Still's disease (including SJIA or AOSD).
• Have data on clinical characteristics and treatments available for at least 3 years following the initiation of canakinumab treatment.
Locations
Other Locations
Switzerland
Novartis
RECRUITING
Basel
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2026-03-15
Estimated Completion Date: 2026-12-03
Participants
Target number of participants: 160
Treatments
FMF Cohort
Patients diagnosed with FMF that received canakinumab for at least 6 months.
SJIA Cohort
Patients diagnosed with SJIA that received canakinumab for at least 6 months.
AOSD Cohort
Patients diagnosed with AOSD that received canakinumab for at least 6 months.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals